GRCE
NASDAQGrace Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.30-0.05 (-2.13%)
03:45 PM07:45 PM
News · 26 weeks17-75%
2025-12-142026-06-07
Mix790d
- Other4(57%)
- SEC Filings3(43%)
Latest news
25 items- SECGrace Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Grace Therapeutics Inc.SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit Application Following Resolution of Cited Items PRINCETON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administ
- PRGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company's STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL. The STRIVE-ON Trial results will be presented as a poster on A
- PRGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesPRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026. The Company is participating in an industry education workshop during the Society of Critical Care Medicine's Critic
- PRGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferencePRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen's 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA. Mr. Kohli's presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateFDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine b
- SECSEC Form 10-Q filed by Grace Therapeutics Inc.10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Grace Therapeutics Inc.SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- INSIDERSEC Form 4 filed by Director Kavuru Vimal4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Neugeboren Edward4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis A Brian4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- INSIDERSEC Form 4 filed by Director Kottayil George4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
- SECAmendment: SEC Form 10-Q/A filed by Grace Therapeutics Inc.10-Q/A - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select ConferencePRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate/present in the upcoming Craig-Hallum 16th Annual Alpha Select Conference, to be held Tuesday, November 18, 2025 in New York, NY. Companies attending the Alpha Select Conference have been individually selected by the Craig-Hallum research team and are
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business UpdateAnnounced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104 PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being
- SECSEC Form 10-Q filed by Grace Therapeutics Inc.10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual MeetingPRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract of the Company's Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) has been accepted for presentation as a late breaking trial at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, to be held November 19-22, 2025 in Orlando, FL.
- SECGrace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
- PRGrace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA ReviewPRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced it has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The Company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining 1,1
GRCE FAQ
5 questionsWhere does GRCE stock trade?
Grace Therapeutics Inc. (GRCE) is listed on NASDAQ.What sector and industry is GRCE in?
Grace Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GRCE?
Grace Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from TD Cowen: Buy with a $1200.00 price target on 2025-05-02. Recent price targets cluster around $1200.00.What companies are similar to GRCE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GRCE side-by-side with any of them on Quantisnow.How can I track GRCE on Quantisnow?
Quantisnow aggregates Grace Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRCE to receive live email and push alerts on every new disclosure.